CA2371728A1 - High dose radionuclide complexes for bone marrow suppression - Google Patents

High dose radionuclide complexes for bone marrow suppression Download PDF

Info

Publication number
CA2371728A1
CA2371728A1 CA002371728A CA2371728A CA2371728A1 CA 2371728 A1 CA2371728 A1 CA 2371728A1 CA 002371728 A CA002371728 A CA 002371728A CA 2371728 A CA2371728 A CA 2371728A CA 2371728 A1 CA2371728 A1 CA 2371728A1
Authority
CA
Canada
Prior art keywords
bone marrow
diseases
high dose
marrow suppression
radionuclide complexes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002371728A
Other languages
French (fr)
Other versions
CA2371728C (en
Inventor
Alan R. Fritzberg
Paul G. Abrams
Lauren M. Tatalick
Kent R. Thoelke
James Kyle Bryan
Elizabeth K. John
Mark D. Hylarides
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Poniard Pharmaceuticals Inc
Original Assignee
Neorx Corporation
Paul G. Abrams
Lauren M. Tatalick
Kent R. Thoelke
James Kyle Bryan
Elizabeth K. John
Mark D. Hylarides
Alan R. Fritzberg
Poniard Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neorx Corporation, Paul G. Abrams, Lauren M. Tatalick, Kent R. Thoelke, James Kyle Bryan, Elizabeth K. John, Mark D. Hylarides, Alan R. Fritzberg, Poniard Pharmaceuticals, Inc. filed Critical Neorx Corporation
Publication of CA2371728A1 publication Critical patent/CA2371728A1/en
Application granted granted Critical
Publication of CA2371728C publication Critical patent/CA2371728C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0478—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group complexes from non-cyclic ligands, e.g. EDTA, MAG3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0489—Phosphates or phosphonates, e.g. bone-seeking phosphonates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present invention relates to a method of suppressing bone marrow (BM) and treating conditions that arise in or near bone such as cancer, myeloproliferative diseases, autoimmune diseases, infectious diseases, metabolic diseases or genetic diseases, with compositions having as their active ingredient a radionuclide complexed with a chelating agent such as macrocyclic aminophosphonic acid.
CA002371728A 1999-06-11 2000-06-12 High dose radionuclide complexes for bone marrow suppression Expired - Fee Related CA2371728C (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US60/139,065 1999-06-11
US13906599P 1999-07-11 1999-07-11
US14378099P 1999-07-13 1999-07-13
US60/143,780 1999-07-13
US14982199P 1999-08-19 1999-08-19
US60/149,821 1999-08-19
PCT/US2000/016052 WO2000076556A2 (en) 1999-06-11 2000-06-12 High dose radionuclide complexes for bone marrow suppression

Publications (2)

Publication Number Publication Date
CA2371728A1 true CA2371728A1 (en) 2000-12-21
CA2371728C CA2371728C (en) 2009-06-02

Family

ID=27385279

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002371728A Expired - Fee Related CA2371728C (en) 1999-06-11 2000-06-12 High dose radionuclide complexes for bone marrow suppression

Country Status (6)

Country Link
US (6) US6767531B2 (en)
EP (1) EP1191948A2 (en)
JP (1) JP2003501488A (en)
AU (1) AU5871000A (en)
CA (1) CA2371728C (en)
WO (1) WO2000076556A2 (en)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2371728C (en) * 1999-06-11 2009-06-02 Neorx Corporation High dose radionuclide complexes for bone marrow suppression
US7094885B2 (en) 1999-07-11 2006-08-22 Neorx Corporation Skeletal-targeted radiation to treat bone-associated pathologies
WO2001091806A2 (en) * 2000-05-31 2001-12-06 Steven Mccullough Measurement of the therapeutic dose for bone marrow ablation therapy
NO313180B1 (en) * 2000-07-04 2002-08-26 Anticancer Therapeutic Inv Sa Visiting alpha particles emitting radiopharmaceuticals
CA2434302A1 (en) * 2001-01-08 2002-08-15 Neorx Corporation Therapeutic and diagnostic compounds, compositions, and methods
US7045116B2 (en) 2001-12-13 2006-05-16 Dow Global Technologies Inc. Treatment of osteomyelitis with radiopharmaceuticals
AU2002368450A1 (en) * 2002-12-10 2004-06-30 University Of Miami Radioablation of hemolymphopoietic cell populations
US20070092440A1 (en) * 2003-05-09 2007-04-26 Edgar Braendle Bone localising radiopharmaceutical and tubulin-interacting compound combinatorial
EP1475105A1 (en) * 2003-05-09 2004-11-10 Schering AG Bone localising radiopharmaceutical and tubulin-interacting compound combinatorial radiotherapy
WO2007008232A2 (en) * 2004-09-03 2007-01-18 Board Of Regents, The University Of Texas System Locoregional internal radionuclide ablation of abnormal tissues.
US8709380B1 (en) * 2006-02-07 2014-04-29 Sirius Medicine, Llc Targeting agents for enhancing radiation therapy
WO2007126730A1 (en) * 2006-03-29 2007-11-08 Isotherapeautics Group Llc Radionuclide therapy for urinary bladder cancer
WO2008060663A2 (en) * 2006-04-14 2008-05-22 Thorenco, Llc Compact neutron generator for medical and commercial isotope production, fission product purification and controlled gamma reactions for direct electric power generation
US8198264B2 (en) * 2006-04-28 2012-06-12 National Cancer Center Method for treating head and neck cancer
TW200809194A (en) * 2006-05-04 2008-02-16 Wyeth Corp Determination of antibiotic concentration in bone
EP2056804B1 (en) * 2006-08-16 2013-05-22 Action Medicines, S.L. Use of 2,5-dihydroxybenzene derivatives for the treatment of ocular diseases
US9993437B2 (en) 2007-12-06 2018-06-12 The Regents Of The University Of California Mesoporous silica nanoparticles for biomedical applications
US20100310465A1 (en) * 2008-01-23 2010-12-09 The Regents Of The University Of California Nano-devices having releasable seals for controlled release of molecules
US9101537B2 (en) 2008-07-25 2015-08-11 Reven Pharmaceuticals, Inc. Compositions and methods for the prevention and treatment of cardiovascular diseases
WO2010078569A2 (en) * 2009-01-05 2010-07-08 Stc.Unm Porous nanoparticle supported lipid bilayer nanostructures
EP2399607B1 (en) * 2009-02-18 2017-11-29 Hisamitsu Pharmaceutical Co., Inc. Transdermal preparation
US20120207795A1 (en) * 2010-07-13 2012-08-16 The Regents Of The University Of California Cationic polymer coated mesoporous silica nanoparticles and uses thereof
CN103327986B (en) 2010-07-22 2018-05-25 雷文制药有限公司 Comprising the treatment using magnetic dipole stabilizing solutions or improve disease and enhance the method for performance
CA2834365A1 (en) 2011-04-28 2012-11-01 Sandia Corporation Porous nanoparticle-supported lipid bilayers (protocells) for targeted delivery and methods of using same
US10220004B2 (en) 2011-07-14 2019-03-05 The Regents Of The University Of California Method of controlled delivery using sub-micron-scale machines
HUE062439T2 (en) * 2013-10-07 2023-11-28 Igl Pharma Inc Process for preparing high purity therapeutic bone agents
RU2599874C2 (en) * 2014-10-13 2016-10-20 Михаил Сергеевич АНОСОВ Method of treatment of chronic odontogenic osteomyelitis in drug-addicts patients
EP3302496B1 (en) * 2015-05-25 2021-01-06 IGL Pharma, Inc. Dotmp kit formulations for radioisotopes
US11369700B2 (en) 2015-05-25 2022-06-28 IGL Pharma Inc. DOTMP kit formulations for radioisotopes
WO2017100162A1 (en) * 2015-12-07 2017-06-15 General Oncology, Inc. Combination for the effective treatment of metastatic cancer in patients
US11672866B2 (en) 2016-01-08 2023-06-13 Paul N. DURFEE Osteotropic nanoparticles for prevention or treatment of bone metastases
WO2018160865A1 (en) 2017-03-01 2018-09-07 Charles Jeffrey Brinker Active targeting of cells by monosized protocells
US10093741B1 (en) 2017-05-05 2018-10-09 Fusion Pharmaceuticals Inc. IGF-1R monoclonal antibodies and uses thereof
CN111263747B (en) 2017-05-05 2023-10-27 探针技术开发及商业化中心 Pharmacokinetic enhancement of difunctional chelates and uses thereof
RU2019139434A (en) 2017-05-05 2021-06-07 Сентр фор Проуб Девелопмент энд Коммерсиализэйшн MONOCLONAL ANTIBODIES AGAINST IGF-1R AND THEIR APPLICATION
MA51056A (en) 2017-12-07 2020-10-14 Reven Ip Holdco Llc COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC DISORDERS
JP2022513399A (en) * 2018-10-29 2022-02-07 モレキュラー ステソスコープ， インコーポレイテッド Bone marrow characterization using cell-free messenger RNA
AR120059A1 (en) * 2019-06-12 2022-02-02 Reven Ip Holdco Llc METHODS AND COMPOSITIONS TO IMPROVE OUTCOMES OF PATIENTS WITH CANCER
AU2021212659A1 (en) 2020-01-28 2022-08-04 Reflexion Medical, Inc. Joint optimization of radionuclide and external beam radiotherapy

Family Cites Families (122)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US589190A (en) * 1897-08-31 Apparatus for compressing air
US118508A (en) * 1871-08-29 Improvement in flour-bolts
US587451A (en) * 1897-08-03 James douglas o neill
US470753A (en) * 1892-03-15 William grunow
US158393A (en) * 1875-01-05 Improvement in grates
US410436A (en) * 1889-09-03 packham
US96393A (en) * 1869-11-02 Improved furniture-caster
US716818A (en) * 1901-04-13 1902-12-23 James A Ekin Criswell Machine for making matches.
US937333A (en) * 1909-06-26 1909-10-19 William H Shugart Rail-joint.
GB750155A (en) 1953-03-17 1956-06-13 Nat Res Dev Substituted alanines
US3032585A (en) 1954-12-03 1962-05-01 Nat Res Dev Process for the production of p-bis-(2-chloroethyl)-aminophenylalanine
US3398097A (en) 1965-07-30 1968-08-20 Progressive Products Co Cleaning composition, and method of cleaning and sequestering metal ions
BE744394A (en) * 1970-01-14 1970-07-14 Elphiac Sa Zone refining process
US3726912A (en) 1970-07-02 1973-04-10 Dow Chemical Co Substituted alkanolamine chelating agents
US3989730A (en) 1972-06-15 1976-11-02 Research Corporation Bone-seeking technetium-99m complex
US3852414A (en) 1972-09-13 1974-12-03 New England Nuclear Corp Bone seeking technetium 99m stannous phosphate complex
PH12898A (en) * 1973-05-23 1979-10-04 Procter & Gamble A composition for the treatment of calcific tumors
US3965254A (en) 1973-05-23 1976-06-22 The Procter & Gamble Company Compositions for the treatment of calcific tumors
US3931396A (en) 1973-05-31 1976-01-06 Commissariat A L'energie Atomique Method of preparation of a composition having a base of 99m technetium for diagnosis by scintigraphy
US4058704A (en) 1974-12-27 1977-11-15 Taeo Kim Coilable and severable heating element
US4017596A (en) 1975-03-03 1977-04-12 Research Corporation Radiopharmaceutical chelates and method of external imaging
US3974268A (en) 1975-05-30 1976-08-10 Research Corporation Bone-seeking technetium-99m imidodiphosphonate complex
DE2543349C2 (en) 1975-09-29 1984-05-10 Henkel KGaA, 4000 Düsseldorf Preparations for the production of 99m technetium-radiagnostica
US4075314A (en) 1976-04-29 1978-02-21 Mallinckrodt, Inc. Stannous pyrophosphate technetium-99m compositions
CA1078731A (en) 1976-12-16 1980-06-03 Charles E. Frosst And Co. Skeletal imaging kit utilizing triethylene tetramine hexa (methylene phosphonic acid)
US4399817A (en) 1981-06-30 1983-08-23 The Procter & Gamble Company Boron containing polyphosphonates for the treatment of calcific tumors
US4957939A (en) 1981-07-24 1990-09-18 Schering Aktiengesellschaft Sterile pharmaceutical compositions of gadolinium chelates useful enhancing NMR imaging
US4647447A (en) 1981-07-24 1987-03-03 Schering Aktiengesellschaft Diagnostic media
US4508625A (en) 1982-10-18 1985-04-02 Graham Marshall D Magnetic separation using chelated magnetic ions
US4707353A (en) * 1982-12-08 1987-11-17 Mallinckrodt, Inc. Radiographic imaging agents
DE3247054C1 (en) * 1982-12-20 1984-05-10 Goetze Ag, 5093 Burscheid Spray powder for the production of wear-resistant coatings
SE8301395L (en) 1983-03-15 1984-09-16 Wallac Oy KELATIZING COMPOUNDS WITH FUNCTIONAL GROUPS WHICH ALLOW COVALENT COUPLING TO BIO-ORGANIC MOLECULES
US4515767A (en) 1983-06-20 1985-05-07 The Dow Chemical Company Radioactive metals complexed with phosphonate derivatives of dicyclopentadienebis(methylamine)
US4676950A (en) * 1984-02-03 1987-06-30 Foster Research Corporation Indicator and test device for detecting occult blood
US4560548A (en) 1984-04-10 1985-12-24 The Dow Chemical Company Bone seeking Tc-99m complexes of phosphonate derivatives of bis(aminoalkyl)piperazine
US5064633A (en) 1984-06-04 1991-11-12 The Dow Chemical Company Macrocyclic aminophosphonic acid complexes, their formulations and use
AU563671B2 (en) 1984-06-04 1987-07-16 Dow Chemical Company, The Organic amine phosphonic acid complexes
US4898724A (en) * 1984-06-04 1990-02-06 The Dow Chemical Company Organis amine phosphonic acid complexes for the treatment of calcific tumors
US5059412A (en) 1984-06-04 1991-10-22 The Dow Chemical Company Macrocyclic aminophosphonic acid complexes for the treatment of calcific tumors
US5066478A (en) 1984-06-04 1991-11-19 The Dow Chemical Company Radio labeled organic amine phosphonic acid complexes for the treatment of calcific tumors
US4606907A (en) 1984-07-02 1986-08-19 The Dow Chemical Company Bone seeking Tc-99m complexes of phosphonate derivatives of polyamidoamines
US4897254A (en) 1984-09-21 1990-01-30 The Dow Chemical Company Radioactive compositions for the treatment of calcific tumors
US4639365A (en) 1984-10-18 1987-01-27 The Board Of Regents, The University Of Texas System Gadolinium chelates as NMR contrast agents
US4678687A (en) * 1984-10-31 1987-07-07 Xerox Corporation Thermal transfer printing sheets containing certain coating compositions thereof
US4897255A (en) 1985-01-14 1990-01-30 Neorx Corporation Metal radionuclide labeled proteins for diagnosis and therapy
US5393512A (en) 1985-01-14 1995-02-28 Vanderheyden; Jean-Luc Stable therapeutic radionuclide compositions and methods for preparation thereof
US5556982A (en) 1985-01-14 1996-09-17 Neorx Corporation Metal radionuclide labeled proteins for diagnosis and therapy
US5288497A (en) * 1985-05-01 1994-02-22 The University Of Utah Compositions of oral dissolvable medicaments
US4752464A (en) 1985-06-07 1988-06-21 Cadema Medical Products, Inc. Treatment of arthritis, including rheumatoid arthritis, with radioactive isotopes
US4678667A (en) 1985-07-02 1987-07-07 501 Regents of the University of California Macrocyclic bifunctional chelating agents
GB8518300D0 (en) 1985-07-19 1985-08-29 Amersham Int Plc Contrast agent
US4885363A (en) 1987-04-24 1989-12-05 E. R. Squibb & Sons, Inc. 1-substituted-1,4,7-triscarboxymethyl-1,4,7,10-tetraazacyclododecane and analogs
DE3772785D1 (en) 1986-01-23 1991-10-17 Squibb & Sons Inc 1-SUBSTITUTED-4,7,10-TRISCARBOXYMETHYL-1,4,7,10-TETRAAZACYCLODODECAN AND ANALOG.
DE3625417C2 (en) 1986-07-28 1998-10-08 Schering Ag Tetraazacyclododecane derivatives
AU608759B2 (en) 1986-08-04 1991-04-18 Amersham Health Salutar Inc NMR imaging with paramagnetic polyvalents metal salts of poly-(acid-alkylene-amido)-alkanes
FR2614020B1 (en) 1987-04-14 1989-07-28 Guerbet Sa NOVEL NITROGEN CYCLIC LIGANDS, METAL COMPLEXES FORMED BY SUCH LIGANDS, DIAGNOSTIC COMPOSITIONS CONTAINING THESE COMPLEXES AND PROCESS FOR PREPARING LIGANDS.
US4853209A (en) * 1987-05-18 1989-08-01 The Dow Chemical Company Bone marrow suppressing agents
US5089249A (en) 1988-06-10 1992-02-18 Neorx Corporation Conjugates for bone imaging and bone cancer therapy
US5202109A (en) 1988-06-10 1993-04-13 Neorx Corporation Conjugates for bone imaging and bone cancer therapy
US4976950A (en) 1988-12-19 1990-12-11 The Dow Chemical Company Bone marrow suppressing agents
US4882142A (en) 1988-12-19 1989-11-21 The Dow Chemical Company Bone marrow suppressing agents
US4937333A (en) 1989-08-04 1990-06-26 The Dow Chemical Company Method for purifying aminomethylenephosphonic acids for pharmaceutical use
GB8903023D0 (en) 1989-02-10 1989-03-30 Parker David Chemical compounds
US5714467A (en) 1989-04-12 1998-02-03 The Rockefeller University Antibacterial and antimalarial hybrid peptides
GB9002375D0 (en) 1990-02-02 1990-04-04 Pfizer Ltd Triazole antifungal agents
US5064433A (en) * 1990-03-05 1991-11-12 Helix Medical, Inc. Voice prosthesis insertion assemblies
CA2057868A1 (en) 1990-04-18 1991-10-19 David Parker Tetra-aza macrocycles processes for their preparation and their use in magnetic resonance imaging
WO1991016075A1 (en) * 1990-04-20 1991-10-31 Australian Nuclear Science & Technology Organisation Bone marrow treatments
ES2071319T3 (en) 1990-06-15 1995-06-16 Hoechst Schering Agrevo Gmbh ANTIFUNGAL POLYPEPTIDE, PROCEDURE FOR ITS PREPARATION.
MC2260A1 (en) * 1990-06-18 1993-04-26 Dow Chemical Co RADIOPHARMACEUTICAL FORMULATIONS, THEIR METHOD OF ADMINISTRATION AND THEIR PREPARATION PROCESS
US5219556A (en) * 1990-07-09 1993-06-15 Mallinckrodt Medical, Inc. Stabilized therapeutic radiopharmaceutical complexes
ES2137929T3 (en) 1990-08-20 2000-01-01 Suntory Ltd DERIVATIVES OF ANTIBACTERIAL PENEM ESTERS.
US5286497A (en) 1991-05-20 1994-02-15 Carderm Capital L.P. Diltiazem formulation
US5861430A (en) 1991-12-17 1999-01-19 Jasmine Fockerman Benzopyran phenol derivates for use as antibacterial, antiviral or immunostimulating agents
US5919925A (en) 1992-01-22 1999-07-06 Pfizer Inc. 2-isocephem and oxacephem derivatives and use as antibacterial agents
US5608060A (en) * 1992-06-09 1997-03-04 Neorx Corporation Biotinidase-resistant biotin-DOTA conjugates
CA2086874E (en) 1992-08-03 2000-01-04 Renzo Mauro Canetta Methods for administration of taxol
JP3756945B2 (en) 1992-10-28 2006-03-22 デン−マット・コーポレーション Antibacterial mouthwash
US5714604A (en) 1993-05-06 1998-02-03 The Dow Chemical Company Process for the preparation of azamacrocyclic or acyclic aminophosphonate ester derivatives
SE9301830D0 (en) 1993-05-28 1993-05-28 Ab Astra NEW COMPOUNDS
TW304159B (en) 1993-08-24 1997-05-01 Janssen Pharmaceutica Nv
US5587451A (en) 1993-11-26 1996-12-24 The Dow Chemical Company Process for preparing polyazamacrocycles
FR2719481B1 (en) 1994-05-05 1996-05-31 Oreal Composition based on antifungal compounds and halogenated antibacterial compounds to reduce hair loss.
WO1996012704A1 (en) 1994-10-20 1996-05-02 Wakunaga Seiyaku Kabushiki Kaisha Novel pyridonecarboxylate derivative or salt thereof and antibacterial containing the same as active ingredient
EP0753001B1 (en) 1994-11-08 1999-09-08 Glaxo Wellcome S.A. Antifungal sordaridin derivatives
AU3696495A (en) 1994-11-17 1996-06-17 F. Hoffmann-La Roche Ag Antibacterial dibenzimidazole derivatives
US5856347A (en) 1994-11-29 1999-01-05 Hisamitsu Pharmaceutical Co., Inc. Antibacterial preparation or bactericide comprising 2-aminothiazole derivative and/or salt thereof
US5773421A (en) 1995-01-10 1998-06-30 Abbott Laboratories Antifungal fusacandins
ES2162039T3 (en) 1995-01-26 2001-12-16 Merck & Co Inc NEW ANTIFUNGIC CYCLOHEXAPEPTIDES.
EP0819759A4 (en) 1995-02-08 1998-04-29 Plant Biolog Defence System La Antifungal terpene compounds and process for proucing the same
JP3081773B2 (en) 1995-03-31 2000-08-28 株式会社資生堂 N-acylpiperazine derivatives and antibacterial and antiulcer agents
US5786325A (en) 1995-05-26 1998-07-28 Eli Lilly And Company Cyclic peptide antifungal agents and methods of making and using
KR100423590B1 (en) 1995-08-02 2004-09-10 호따. 우리아치에씨아. 에세. 아. New pyrimidone derivatives with antifungal activity
MX9702380A (en) 1995-08-02 1998-02-28 Uriach & Cia Sa J New carboxamides with antifungal activity.
US5681430A (en) * 1995-08-23 1997-10-28 Thermo Fibertek Inc. Activity induction in papermaking
US5872249A (en) 1995-09-01 1999-02-16 Korea Institute Of Science And Technology 3-ammoniopropenyl cephalosporin compounds as antibacterial agents and process for preparing the same
US5760063A (en) 1995-09-15 1998-06-02 Scriptgen Pharmaceuticals, Inc. Arylhydrazone derivatives useful as antibacterial agents
ATE229014T1 (en) 1995-09-15 2002-12-15 Upjohn Co ALPHA,BETA-SATURATED AND -UNSATURATED 3-ARYL-5- AMINOMETHYL-BUTYROLACTONE ANTIBACTERIAL AGENTS
US5837726A (en) 1995-11-01 1998-11-17 Millennium Pharmaceuticals, Inc. Antifungal agents derived from aspergillus fumigatus
EP0781566B1 (en) 1995-12-26 2004-07-28 Toyo Boseki Kabushiki Kaisha Organic solvent-soluble mucopolysaccharide, antibacterial antithrombogenic composition and medical material
US5756472A (en) 1996-01-31 1998-05-26 Merck & Co., Inc. Antifungal agent obtained from hormonema
JP4058129B2 (en) 1996-03-18 2008-03-05 株式会社資生堂 Pyridine derivatives and anti-ulcer agents, antibacterial agents
US5770617A (en) 1996-03-20 1998-06-23 Rutgers, The State University Of New Jersey Terbenzimidazoles useful as antifungal agents
US5773696A (en) 1996-03-29 1998-06-30 Monsanto Company Antifungal polypeptide and methods for controlling plant pathogenic fungi
JP3693449B2 (en) 1996-04-05 2005-09-07 三菱製紙株式会社 Antibacterial antifungal agent and fibrous substance containing the same
JP4150435B2 (en) 1996-04-18 2008-09-17 株式会社資生堂 Alkylene diamine derivatives and anti-ulcer agents, antibacterial agents
US5756725A (en) 1996-04-24 1998-05-26 Merck & Co., Inc. Carbapenem antibacterial compounds, compositions containing such compounds and methods of treatment
US5917084A (en) 1996-07-03 1999-06-29 Millennium Pharmaceuticals, Inc. Antifungal agents
GB2315489A (en) 1996-07-17 1998-02-04 Merck & Co Inc Antifungal agent
US5837253A (en) 1996-07-26 1998-11-17 Agrogene Ltd. Preparation and use of Inula extracts as a fungicide for the control of plant diseases
US5908862A (en) 1996-07-31 1999-06-01 Abbot Laboratories Water-miscible esters of mono--and diglycerides having antibacterial activity and their use in inhibiting infection
UA51730C2 (en) 1996-09-04 2002-12-16 Ебботт Лабораторіз 6-0-substituted ketolides having antibacterial activity
US5830855A (en) 1996-09-12 1998-11-03 Utah State University Lipodepsipeptides as antifungal and fungicidal agents
US5876738A (en) 1996-10-29 1999-03-02 Toagosei Co., Ltd. Antifungal phyllosilicate
US6005083A (en) * 1997-03-28 1999-12-21 Neorx Corporation Bridged aromatic substituted amine ligands with donor atoms
JP4090087B2 (en) 1997-04-04 2008-05-28 株式会社資生堂 Benzamide derivatives and anti-ulcer agents, antibacterial agents
US5863773A (en) 1997-09-30 1999-01-26 Abbott Laboratories Antifungal corynecandin
DE19911329A1 (en) 1998-03-27 2000-09-21 Benes Ivan Friedrich Radioimmunoconjugate which can be used in human therapy and process for its preparation
CA2371728C (en) * 1999-06-11 2009-06-02 Neorx Corporation High dose radionuclide complexes for bone marrow suppression
US7094885B2 (en) 1999-07-11 2006-08-22 Neorx Corporation Skeletal-targeted radiation to treat bone-associated pathologies
CA2434302A1 (en) * 2001-01-08 2002-08-15 Neorx Corporation Therapeutic and diagnostic compounds, compositions, and methods
US7045116B2 (en) * 2001-12-13 2006-05-16 Dow Global Technologies Inc. Treatment of osteomyelitis with radiopharmaceuticals

Also Published As

Publication number Publication date
WO2000076556A2 (en) 2000-12-21
US20090136419A1 (en) 2009-05-28
US20050063905A1 (en) 2005-03-24
WO2000076556A3 (en) 2001-10-11
US20050238578A1 (en) 2005-10-27
WO2000076556A9 (en) 2001-11-08
US7378077B2 (en) 2008-05-27
CA2371728C (en) 2009-06-02
US6767531B2 (en) 2004-07-27
US7097823B2 (en) 2006-08-29
JP2003501488A (en) 2003-01-14
US20070053833A1 (en) 2007-03-08
US7070759B2 (en) 2006-07-04
US7696331B2 (en) 2010-04-13
AU5871000A (en) 2001-01-02
EP1191948A2 (en) 2002-04-03
US7408046B2 (en) 2008-08-05
US20050129667A1 (en) 2005-06-16
US20020176818A1 (en) 2002-11-28

Similar Documents

Publication Publication Date Title
CA2371728A1 (en) High dose radionuclide complexes for bone marrow suppression
IE940833L (en) Macrocyclic aminophosphonic acid complexes, their¹preparation, formulations and use
WO2001024763A3 (en) Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
HK1053115A1 (en) Quinazoline derivatives for the treatment of tumours.
CA2003326A1 (en) Bone marrow suppressing agents
WO2001072721A3 (en) Synergistic methods and compositions for treating cancer
NZ337527A (en) Water-soluble pharmaceutical composition comprising an ionic complex of a polypeptide and an amphiphilic compound and a method for increasing the activity of a polypeptide by forming the aforementioned complex
CA2366702A1 (en) Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
EP1100522A4 (en) Pulmonary delivery of active agents
EP1024145A3 (en) Novel azalides and methods of making same
WO2000053730A3 (en) Medical preparations for the treatment of alpha-galactosidase a deficiency
WO2002085299A3 (en) Therapeutic treatments using the direct application of antimicrobial metal compositions
ES2033196A1 (en) Water-dispersible granules of phosphite fungicidal products
EP2767291A3 (en) Treatment of glycogen storage disease type II
AU3956599A (en) Surfactant for use in external preparations for skin and external preparation for skin containing the same
EP1178988A4 (en) Compounds and therapeutic methods
NZ319138A (en) Composition containing cytochrome complex III and fenazaquin for combatting parasitic fungi
NZ511172A (en) Buffered compositions for dialysis
EP0281070A3 (en) Pharmaceutical composition for the treatment of cancer
UA74388C2 (en) Pharmaceutical compositions of tysoxanide and nitasoxanide
WO2003053365A3 (en) Syn3 compositions and methods
WO2001074401A3 (en) Camptothecin complexes
WO1994020115A3 (en) Hyaluronic acid used as a cancer treatment
WO2002076400A3 (en) Inosine compounds and their use for treating or preventing an inflamation or a reperfusion disease
IN181999B (en)

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20130612